This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What could the implications be for patients on their medical cannabis journey? Rescheduling would stand to have the largest impact on cannabis research and business taxes. Cannabis research The Controlled Substances Act requires scientists to register with the DEA if they want to research Schedule I substances.
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
The Office of Drug Control (ODC) issues several license types, including: Cultivation growing cannabis for medicinal or research purposes. Research studying cannabis for medicinal development. Businesses should also investigate potential research and development (R&D) incentives if applicable.
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. RYAH Group Inc.
Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.
Published in Nature , the study found that just under a third of patients report significant improvements and over half report moderate improvements while using CBD -rich oil derived from cannabis (30% CBD , 1-2% THC ). Previous research has found that THC may be effective for some cases that do not respond well to Ritalin. .
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem. What makes a good research study, anyway?
Also introduced was The Marijuana Data Collection Act of 2019 , which would study the effects of state legalized medicinal and non-medicinal marijuana programs from a variety of perspectives, including state revenues, public health, substance abuse and opioids, criminal justice, and employment.
.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.
In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 Furthermore, 25.4%
According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. Other Research Findings.
Cancer patients arguably stand to benefit the most from cannabis’ unique properties and benefits, such as anti-nausea, anti-inflammation, reduced pain, inhibited tumor growth, and appetite stimulation. Additionally, the increase in the availability of cannabis research has led to a decrease in stigmatization attached to cannabis.
CanMar Recruitment is looking for a Director of Business Development and Partnerships for our client in Montreal, Quebec. As Director of Business Development and Partnerships, you are responsible for leading and accelerating business analysis, sourcing, and deal flow activities. About Our Client. About the Role. Responsibilities.
– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Declining circulating tumor cell (CTC) count in treated patients.
Let’s take a closer look at this new research around CBD for Cerebral Palsy and examine the extent of this trend and its implications for the future of CP management. It occurs due to abnormalities or damage to the developing brain before, during, or after birth. What is Cerebral Palsy?
annually — is one of the most common reasons why medical marijuana is sought out by patients in the United States, Canada, and beyond. New guidelines for cannabis in chronic pain were recently published by a group of Canadian researchers. How Were the New Guidelines for Cannabis in Chronic Pain Developed?
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Clinical trials are medical research projects involving human participants.
On top of recognizing the vast scope of benefits cannabis can provide, patients are saving lots of hard-earned money by swapping their pills for cannabis. People often associate pharmaceuticals with being man-made, but some pharmaceutical companies are developing medications made with natural ingredients. pharmaceuticals).
Until recently, there has been little to no research available that examines the effects of cannabis in patients diagnosed with Obsessive-Compulsive Disorder (OCD). Many patients with OCD tend to perform actions without wanting to, but feeling powerless to try and stop it. What Does Research Say About Cannabis and OCD?
Fernando Fandio-Sende, LifeCannMD After thirty years practicing medicine and specializing as a Miami cannabis doctor , I’ve had countless conversations with patients who tell me the same thing: “Doctor, I want to try medical marijuana , but I’m scared of getting too high.”
The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. . – July 28, 2021) – PharmaDrug Inc.
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.
These essential oils are called Terpenes, and while research is still evolving, science has proven that these oils can drastically improve a patient’s quality of life. This efficacy translates to better medicine and better treatments for patients. Over 100 cannabis-based Terpenes have been discovered. Dogwalker OG.
Scientists had published legitimate research findings showing that cannabis compounds had actually slowed tumor growth in mice. For an engineer like Rick, who understood the value of evidence and data, it was a revelation. He developed a concentrated oil from the cannabis plant and decided to try it on himself.
At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value. As a result, medical and scientific research has been highly constrained for many decades. Exponential Increase in Cannabis Research: Trends.
Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. Some people have different flashback experience.
The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? President, Director and Chief Medical Officer of MyMD.
Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.
Artificial intelligence is a smarter, faster, and more effective pathway to drug development. With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions.
Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.
Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. Ehave, Inc. Forward-Looking Statement Disclaimer.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.
Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Once known solely as a party drug, ketamine is starting to earn a new reputation thanks to research efforts into its potentially medicinal qualities.
A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
This is according to a group of researchers from the University of New Mexico (UNM) , who recently teamed up with the creators of the Releaf App to investigate the true link between cannabis use and energy levels. Data was pulled from 3,922 cannabis self-administration sessions with the help of this application.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.
Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content